Bayer's AskBio Completes Enrollment in Phase 2 Heart Failure Gene Therapy Trial
Bayer AG (BAYZF:OTCMKTS) announced that its subsidiary, AskBio, has completed enrollment for a Phase 2 clinical trial of an experimental gene therapy targeting chronic heart failure. The trial is evaluating the safety and efficacy of AAV5-TRC1048 in patients with dilated cardiomyopathy caused by mutations in the TTN gene. Initial data from the GenePHIT trial are expected to be released in early 2027. This milestone marks a significant step forward for AskBio's pipeline and highlights Bayer’s ongoing commitment to advancing innovative therapies in cardiovascular disease. The completion of enrollment suggests that the company is on track with its clinical development timeline, potentially setting up key data readouts within the next year or so.
